@entity308 ( @entity2175 ) are common comorbid diseases and highly prevalent in the clinical setting with an unclarified mechanism. @entity6 ( @entity6 , fa/fa) @entity35 natively develop @entity2175 with @entity4854 and @entity3190 . Here we studied whether @entity6 @entity35 also innately develop @entity308 , what a correlation is between @entity308 and @entity2175 , whether @entity8683 ( @entity8683 ) expression is involved in, and whether transcutaneous auricular vagus nerve stimulation (taVNS) would be beneficial in amelioration of the comorbidity. Six week old male @entity6 and Zucker lean (ZL, fa/+) littermates were randomly divided into na  ve ( @entity6 , n=6; ZL, n=7) and taVNS ( @entity6 -taVNS, n=8; ZL-taVNS, n=6) groups. Once daily 30 min-taVNS sessions were administrated under anesthesia for 34 consecutive days in taVNS groups. Blood @entity413 levels were tested weekly, and plasma glycosylated hemoglobin (HbAlc) level and immobility time in forced swimming test were determined on day 35 in all groups. The expression of @entity8683 ( @entity8683 ) in various tissues was also detected by immunostaining and Western blot. We found that na  ve @entity6 @entity35 developed @entity4854 steadily. These @entity6 @entity35 showed a strong positive correlation between longer immobility time and higher plasma HbAlC level. Long term taVNS treatment simultaneously prevented the development of @entity308 -like behavior and progression of @entity4854 in @entity6 @entity35 . The expression of @entity8683 in various tissues of na  ve @entity6 @entity35 is lower than in na  ve ZL and long-term taVNS treated @entity6 @entity35 . Collectively, our results indicate that in @entity6 @entity35 , i) @entity308 and @entity2175 develop simultaneously, ii) immobility time and HbAlc concentrations are highly and positively correlated, iii) a low expression of @entity8683 may be involved in the comorbidity of @entity308 and @entity2175 , and iv) taVNS is antidiabetic and antidepressive possibly through @entity8683 expression upregulation.

Therapeutic effect of vagus nerve stimulation on XXXX -like behavior, @entity4854 and @entity8683 expression in Zucker fatty @entity35 .

@entity2175 :: ('MESH:D003924', 'Disease') :: ['T2D'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression', 'Depression and type 2 diabetes'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Zucker diabetic fatty', 'ZDF'] @entity3190 :: ('MESH:D006946', 'Disease') :: ['hyperinsulinemia'] @entity8683 :: ('24954(Tax:10116)', 'Gene') :: ['insulin receptor', 'IR'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity308 :: (MESH:D003866,Disease) :: ['depressive']
